KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Finished Goods (2016 - 2021)

Historic Finished Goods for Biomarin Pharmaceutical (BMRN) over the last 12 years, with Q3 2021 value amounting to $261.6 million.

  • Biomarin Pharmaceutical's Finished Goods fell 2078.72% to $261.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $261.6 million, marking a year-over-year decrease of 2078.72%. This contributed to the annual value of $313.6 million for FY2020, which is 2256.51% up from last year.
  • Biomarin Pharmaceutical's Finished Goods amounted to $261.6 million in Q3 2021, which was down 2078.72% from $253.3 million recorded in Q2 2021.
  • In the past 5 years, Biomarin Pharmaceutical's Finished Goods registered a high of $330.3 million during Q3 2020, and its lowest value of $129.6 million during Q2 2017.
  • In the last 5 years, Biomarin Pharmaceutical's Finished Goods had a median value of $220.9 million in 2018 and averaged $226.5 million.
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 7009.23% in 2018, then tumbled by 2078.72% in 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's Finished Goods (Quarter) stood at $191.2 million in 2017, then rose by 17.76% to $225.2 million in 2018, then rose by 13.62% to $255.9 million in 2019, then grew by 22.57% to $313.6 million in 2020, then fell by 16.56% to $261.6 million in 2021.
  • Its Finished Goods stands at $261.6 million for Q3 2021, versus $253.3 million for Q2 2021 and $279.6 million for Q1 2021.